FDA Schedules July 2026 PCAC Review of BPC-157, TB-500, MOTs-C, KPV, Semax, Epitalon, DSIP

The FDA has scheduled its Pharmacy Compounding Advisory Committee (PCAC) to meet on July 23 and 24, 2026, to weigh whether seven peptides should be added to the 503A bulks list. The agenda includes BPC-157, TB-500, MOTs-C, KPV, Semax, Epitalon, and DSIP. The committee’s recommendations are non-binding, but they often shape what the FDA later allows compounding pharmacies to prepare for patients.

Details

The 503A bulks list governs which active ingredients licensed pharmacists can use when compounding medicines for individual patients without an approved drug monograph. According to the FDA’s advisory committee calendar, the July 23 and 24 meeting will hear presentations on each substance and take public comment.

The agency posted two public comment dates. Comments received on or before July 9, 2026, will be provided to the committee. The docket closes on July 22, 2026, and comments submitted after July 9 but before the docket closes will still be taken into consideration by FDA. Comments can be filed through Regulations.gov.

The peptides on the agenda cover several research areas. BPC-157 and TB-500 are best known for tissue and tendon repair claims. MOTs-C is a mitochondrial-derived peptide tied to metabolic studies. KPV is a small fragment of alpha-MSH studied for gut and skin inflammation. Semax is a Russian-developed nootropic. Epitalon is a four-amino-acid compound associated with longevity research. DSIP, or delta sleep-inducing peptide, has a small base of sleep-related literature.

Notably, GHK-Cu is not on this July agenda. The FDA’s category-2 page says GHK-Cu has been withdrawn from category 2, and the agency plans to consult PCAC about it before the end of February 2027. That review is separate from the July meeting.

Reuters reported on April 15, 2026, that the panel will consider broader compounding access for peptides that have been popular in wellness clinics but lack approved drug monographs.

Why It Matters

For people who follow this space, the PCAC review is the closest thing to a formal signal from the FDA on whether these compounds belong in legitimate pharmacy practice. A favorable recommendation would not legalize over-the-counter sale, and it would not approve any of these peptides as drugs. It would, however, give state-licensed compounding pharmacies a clearer path to prepare them for patients holding a valid prescription.

A negative recommendation would push these peptides further toward research-only status. That category is what created much of the legal gray zone the community has felt since 2023, when the FDA put several peptides into category 2 over safety and identity questions.

It’s worth being clear about scope. The committee is advisory. Its recommendations are not law. The agency can accept, reject, or revise what PCAC suggests. This July meeting is not an approval event, and it does not change current legal access on its own.

What’s Next

The two-day open session runs July 23 and 24, 2026. After the meeting, the FDA is expected to publish meeting materials and any committee recommendations. The agency typically takes several months to a year to issue final positions on bulks list candidates, and any rule change usually goes through a separate notice and comment process.

Watch for a separate PCAC discussion on GHK-Cu, which the FDA says it intends to schedule before the end of February 2027. The peptide community will likely treat that as the next major regulatory checkpoint after the July review.

For now, the legal picture has not changed. Patients should continue to talk with a licensed clinician and pharmacist about any compounded peptide therapy, and check state-level rules, which in some cases are stricter than federal guidance. We will follow the briefing materials, public comments, and the agency’s response once the meeting wraps up.

Related Reading

• Are Peptides Legal: FDA Regulations 2026
• BPC-157 Complete Guide
• Peptide Legality FDA RFK Guide